Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment

Diagnostics & Research is Zen Rated C and is the 67th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
QGEN	QIAGEN NV	$8.96B	217,685,000	82.15%	0.00%
SHC	SOTERA HEALTH CO	$3.64B	283,855,074	66.68%	33.32%	Net Selling	Net Selling
ILMN	ILLUMINA INC	$12.38B	158,300,000	93.36%	6.64%	Net Selling	Net Selling
A	AGILENT TECHNOLOGIES INC	$31.79B	285,102,717	88.41%	1.23%	Net Buying	Net Buying
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$6.82B	49,115,712	96.87%	3.13%	Net Selling	Net Buying
RVTY	REVVITY INC	$10.73B	117,869,660	94.47%	2.70%	Net Selling	Net Selling
DHR	DANAHER CORP	$134.42B	715,669,594	75.47%	24.53%	Net Selling	Net Selling
WAT	WATERS CORP	$20.55B	59,509,089	92.54%	7.46%	Net Selling	Net Selling
IDXX	IDEXX LABORATORIES INC	$40.97B	80,421,917	89.10%	1.77%	Net Selling	Net Buying
DGX	QUEST DIAGNOSTICS INC	$19.25B	111,635,472	88.44%	1.77%	Net Selling	Net Selling
LH	LABCORP HOLDINGS INC	$20.29B	83,700,000	92.85%	1.53%	Net Selling	Net Selling
IQV	IQVIA HOLDINGS INC	$24.53B	173,000,000	52.53%	47.47%	Net Selling
MEDP	MEDPACE HOLDINGS INC	$8.38B	28,741,609	27.80%	72.20%	Net Buying	Net Buying
FONR	FONAR CORP	$80.61M	6,585,978	47.25%	3.58%
MYNZ	MAINZ BIOMED NV	$5.25M	2,319,353	10.58%	0.00%
TMO	THERMO FISHER SCIENTIFIC INC	$153.28B	377,493,912	89.28%	0.89%	Net Selling	Net Selling
MYGN	MYRIAD GENETICS INC	$353.96M	92,177,383	91.86%	8.14%	Net Selling	Net Selling
ACRS	ACLARIS THERAPEUTICS INC	$127.77M	108,281,239	57.60%	42.40%	Net Buying	Net Selling
FLGT	FULGENT GENETICS INC	$598.52M	30,443,595	45.21%	54.79%	Net Selling	Net Selling
NTRA	NATERA INC	$20.66B	136,546,580	79.40%	20.60%	Net Selling	Net Selling
EXAS	EXACT SCIENCES CORP	$10.35B	188,637,673	96.73%	3.27%	Net Selling	Net Selling
GH	GUARDANT HEALTH INC	$5.04B	123,888,045	65.53%	34.47%	Net Selling	Net Selling
XGN	EXAGEN INC	$104.77M	18,002,416	33.56%	62.05%	Net Selling	Net Selling
CDNA	CAREDX INC	$892.00M	55,680,549	77.83%	22.17%	Net Selling	Net Selling
NEO	NEOGENOMICS INC	$1.02B	128,694,503	71.77%	28.23%	Net Buying	Net Buying
ADVB	ADVANCED BIOMED INC	$25.75M	21,640,000	0.00%	0.00%
MTD	METTLER TOLEDO INTERNATIONAL INC	$23.23B	20,782,786	94.86%	4.67%	Net Selling	Net Buying
TWST	TWIST BIOSCIENCE CORP	$1.77B	59,916,141	87.81%	12.19%	Net Selling	Net Selling
PSNL	PERSONALIS INC	$425.73M	88,325,138	58.42%	40.92%	Net Buying
GRAL	GRAIL INC	$1.18B	35,973,494	73.08%	26.92%	Net Buying	Net Selling
STIM	NEURONETICS INC	$283.03M	65,820,344	11.47%	65.63%	Net Buying	Net Selling
ICLR	ICON PLC	$10.51B	79,464,252	95.64%	0.00%
NOTV	INOTIV INC	$70.08M	34,352,978	25.67%	39.41%	Net Buying	Net Selling
OCX	ONCOCYTE CORP	$74.36M	28,599,285	9.32%	90.68%	Net Buying
APDN	APPLIED DNA SCIENCES INC	$923.86k	1,103,770	9.60%	90.40%
SERA	SERA PROGNOSTICS INC	$84.76M	37,672,784	48.06%	25.72%	Net Selling	Net Selling
RDNT	RADNET INC	$4.53B	75,030,098	67.41%	32.59%	Net Selling	Net Buying
DRIO	DARIOHEALTH CORP	$29.01M	43,949,424	17.65%	37.31%	Net Buying
OPK	OPKO HEALTH INC	$999.25M	793,052,803	20.04%	79.96%	Net Buying	Net Buying
NEOG	NEOGEN CORP	$1.38B	217,038,267	98.56%	1.44%	Net Buying	Net Buying
LAB	STANDARD BIOTOOLS INC	$406.41M	379,822,268	55.81%	44.19%	Net Buying	Net Buying
CSTL	CASTLE BIOSCIENCES INC	$471.20M	28,872,315	85.52%	14.48%	Net Selling	Net Selling
BNR	BURNING ROCK BIOTECH LTD	$28.09M	107,613,971	2.17%	0.00%
ISPC	ISPECIMEN INC	$2.93M	2,496,858	0.55%	99.45%
XWEL	XWELL INC	$4.71M	5,261,024	1.49%	98.51%	Net Buying
PRPH	PROPHASE LABS INC	$15.41M	41,879,017	5.78%	24.64%
CHEK	CHECK-CAP LTD	$5.68M	5,851,042	2.33%	0.00%
BDSX	BIODESIX INC	$32.24M	146,563,031	40.03%	52.55%	Net Buying	Net Selling
TRIB	TRINITY BIOTECH PLC	$6.13M	153,310,284	1.70%	0.00%
PRPO	PRECIPIO INC	$10.48M	1,512,011	0.30%	99.70%	Net Buying	Net Buying
BIAF	BIOAFFINITY TECHNOLOGIES INC	$4.11M	18,255,824	2.93%	26.34%
NDRA	ENDRA LIFE SCIENCES INC	$1.76M	562,213	0.01%	99.99%	Net Buying
PRE	PRENETICS GLOBAL LTD	$75.26M	12,984,844	8.77%	0.00%
VNRX	VOLITIONRX LTD	$45.47M	96,543,744	19.36%	37.75%	Net Buying	Net Buying
STRR	STAR EQUITY HOLDINGS INC	$7.54M	3,209,340	0.95%	99.05%	Net Buying
MDXH	MDXHEALTH SA	$8.81M	49,497,334	23.84%	76.16%

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in May 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the #1 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Qiagen Nv (NYSE:QGEN) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: B.

Qiagen Nv (NYSE:QGEN) has a Due Diligence Score of 23, which is -4 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates QGEN as a "A".

QGEN passed 9 out of 38 due diligence checks and has weak fundamentals. Qiagen Nv has seen its stock lose -9.34% over the past year, overperforming other diagnostic & research stocks by 20 percentage points.

Qiagen Nv has an average 1 year price target of $48.25, an upside of 17.25% from Qiagen Nv's current stock price of $41.15.

Qiagen Nv stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Qiagen Nv, 25% have issued a Strong Buy rating, 0% have issued a Buy, 75% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #2 top diagnostic & research stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: A, Financials: C, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 21, which is -6 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates SHC as a "B".

SHC passed 7 out of 33 due diligence checks and has weak fundamentals. Sotera Health Co has seen its stock return 12.37% over the past year, overperforming other diagnostic & research stocks by 42 percentage points.

Sotera Health Co has an average 1 year price target of $14.75, an upside of 15.14% from Sotera Health Co's current stock price of $12.81.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Sotera Health Co, 50% have issued a Strong Buy rating, 25% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the #3 top diagnostic & research stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: B, Growth: A, Momentum: F, Sentiment: D, Safety: B, Financials: B, and AI: C.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 20, which is -7 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates ILMN as a "B".

ILMN passed 6 out of 33 due diligence checks and has weak fundamentals. Illumina has seen its stock lose -32.33% over the past year, underperforming other diagnostic & research stocks by -3 percentage points.

Illumina has an average 1 year price target of $109.60, an upside of 40.14% from Illumina's current stock price of $78.21.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Illumina, 30% have issued a Strong Buy rating, 10% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 10% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.33%, which is 1 percentage points higher than the diagnostic & research industry average of 0.61%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

2. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.65%, which is the same as the diagnostic & research industry average of 0.61%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 21.9% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.59%, which is the same as the diagnostic & research industry average of 0.61%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 33% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -3.89% in the last day, and up 0.27% over the last week. Biodesix was the among the top losers in the diagnostics & research industry, dropping -38.72% yesterday.

Biodesix shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 sales guidance below estimates.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 57, which is 42 points higher than the diagnostic & research industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Icon's stock has dropped -58.1% in the past year. It has underperformed other stocks in the diagnostic & research industry by -29 percentage points.

2. Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific (NYSE:TMO) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Thermo Fisher Scientific has a valuation score of 29, which is 14 points higher than the diagnostic & research industry average of 15. It passed 2 out of 7 valuation due diligence checks.

Thermo Fisher Scientific's stock has dropped -31.73% in the past year. It has underperformed other stocks in the diagnostic & research industry by -2 percentage points.

3. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Illumina has a valuation score of 0, which is -15 points higher than the diagnostic & research industry average of 15. It passed 0 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates ILMN a Valuation Rating of "B".

Illumina's stock has dropped -32.33% in the past year. It has underperformed other stocks in the diagnostic & research industry by -3 percentage points.

Are diagnostic & research stocks a good buy now?

51.22% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 22.75% over the next year.

2.38% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 16.67% of diagnostic & research stocks are rated B (Buy), 66.67% are rated C (Hold), 14.29% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 19.46x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

Diagnostic & Research Stocks FAQ

1. Qiagen Nv (NYSE:QGEN)

2. Sotera Health Co (NASDAQ:SHC)

3. Illumina (NASDAQ:ILMN)

1. Quest Diagnostics (NYSE:DGX)

2. Agilent Technologies (NYSE:A)

3. Labcorp Holdings (NYSE:LH)

1. Icon (NASDAQ:ICLR)

2. Thermo Fisher Scientific (NYSE:TMO)

3. Illumina (NASDAQ:ILMN)

Company

Stock Tools

Stock Ideas